Spero Therapeutics, Inc. (SPRO) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Spero Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for rare diseases and multi-drug resistant (MDR) bacterial infections. The company has no approved products and relies on government grants and collaboration agreements for revenue. Key programs include SPR720 (oral agent for NTM pulmonary disease), tebipenem HBr (oral carbapenem for cUTIs, partnered with GSK), and SPR206 (IV antibiotic for MDR Gram-negative infections).
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | Q2 2023 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Total Revenue | $10.2 million | $2.7 million | $19.5 million | $4.8 million |
| Net Loss | $(17.9) million | $(11.9) million | $(30.5) million | $(25.2) million |
| Net Loss Per Share | $(0.33) | $(0.23) | $(0.57) | $(0.48) |
| Cash and Cash Equivalents | $63.5 million (as of June 30, 2024) | |||
| Accumulated Deficit | $(421.6) million (as of June 30, 2024) | |||
| Operating Cash Flow (YTD) | $(12.8) million used | $(31.4) million used |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased significantly year-over-year, driven primarily by collaboration revenue from GSK ($5.9 million in Q2 2024 vs. $0.5 million in Q2 2023) and increased grant revenue from BARDA ($4.1 million in Q2 2024 vs. $1.0 million in Q2 2023).
- Expense Increase: Operating expenses rose to $29.3 million in Q2 2024 from $15.6 million in Q2 2023. Research and Development (R&D) expenses increased by $14.2 million, largely due to clinical activities for the SPR720 Phase 2a trial and the tebipenem HBr Phase 3 trial.
- Cash Position: Cash and cash equivalents decreased by $12.8 million during the six months ended June 30, 2024, compared to a decrease of $31.4 million in the prior year period, reflecting improved cash flow management and milestone collections.
Guidance, Outlook, and Risks
- Cash Runway: Management believes current cash ($63.5 million) plus expected collections from collaboration receivables will fund operations into late 2025. Additional funding will be required thereafter.
- Clinical Updates:
- SPR720: Enrollment in the Phase 2a proof-of-concept trial concluded in July 2024. Preliminary data on early bactericidal activity is expected in Q4 2024.
- tebipenem HBr: In July 2024, BARDA executed a contract modification adding $11.7 million in funding, bringing total committed funding to $59.3 million.
- SPR206: Received FDA Fast Track designation in March 2024 for hospital-acquired bacterial pneumonia.
- Legal Proceedings: The company is defending against two consolidated putative class action lawsuits and two derivative lawsuits alleging false/misleading statements regarding the tebipenem HBr NDA. The company denies wrongdoing and intends to vigorously defend these actions.
- Personnel Changes: Dr. Kamal Hamed, Chief Medical Officer, is departing effective August 29, 2024. The company is conducting an executive search for a successor.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the "late 2025" cash runway given the increased R&D spend and potential delays in clinical milestones.
- GSK Milestone Collections: Confirm the timing and certainty of remaining installment payments from the $95 million GSK development milestone.
- Legal Exposure: Monitor the status of the consolidated class action and derivative lawsuits, as a negative outcome could result in substantial costs and reputational damage.
- SPR720 Data Readout: Assess the Q4 2024 preliminary data release for SPR720 as a critical catalyst for the company's lead asset.
- Government Contract Compliance: Review the terms of the BARDA and NIAID contracts for any compliance risks that could impact future funding.